Nanocrystalline Epstein-Barr virus decoys.
A novel biotechnology is introduced by way of the successful synthesis of nanocrystalline Epstein-Barr virus (EBV) decoys having specific in vivo immunogenic activity.  Assembled from ultrafine surface modified tin oxide and purified DNA-free isolated EBV envelope proteins, the decoys consisted of less than 150 nm units whose electrophoretic mobilities were similar to whole EBV; whose outer coats were strongly immunoreactive with murine monoclonal anti-EBV antibodies; and which elicited immunospecific neutralizing anti-EBV antibodies in the rabbit.  The development of this carrier technology for vaccine preparations is suggested.
Kossovsky
N
N
Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Los Angeles 90024.
Gelman
A
A
Sponsler
E
E
Millett
D
D
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D004337:Drug Carriers; D004353:Drug Evaluation, Preclinical; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D008565:Membrane Proteins; D010316:Particle Size; D011817:Rabbits; D013499:Surface Properties; D013501:Surface-Active Agents; D014001:Tin; D014759:Viral Envelope Proteins; D014765:Viral Vaccines